Position in LYEL
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$272,710
-$14,324 QoQ
Shares Held
19,410
+86.6% QoQ
Ownership
0.079%
of shares outstanding
% of Portfolio
0.07%
of 13F equity value
Holder Rank
#43
of 87 holders
Holding Since
Dec 2023
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LYEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026EntryPoint Capital, LLC holds $21,800,288 across 60 Biotechnology names. LYEL ranks #36 (1.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UPB |
Upstream Bio, Inc.
|
129,446 | $895,766 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
25,766 | $860,326 | |
| 3 | AUPH |
Aurinia Pharmaceuticals Inc.
|
48,218 | $818,259 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
13,177 | $795,363 | |
| 5 | FULC |
Fulcrum Therapeutics, Inc.
|
217,199 | $794,948 | |
| 6 | INCY |
Incyte Corp
|
6,483 | $734,912 | |
| 7 | IMCR |
Immunocore Holdings plc
|
22,815 | $724,376 | |
| 8 | RVMD |
Revolution Medicines, Inc.
|
3,574 | $669,338 |
All Filings in LYEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $272,710 | 19,410 | Shares | Sole | 2026-08-13 | |
| 2024-09-30 | $287,034 | 207,996 | Shares | Sole | 2024-11-13 | |
| 2024-06-30 | $269,323 | 185,740 | Shares | Sole | 2026-08-13 | |
| 2024-03-31 | $59,601 | 26,727 | Shares | Sole | 2024-05-14 | |
| 2023-12-31 | $127,328 | 65,633 | Shares | Sole | 2024-02-14 | |
| No filing history on record for this holder in this stock. | ||||||